drugset / Trial / NCT01485601

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines

NCT01485601

Phase 2 Completed 121 enrolled Medy-Tox
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to find an optimal dose to determine the safety and tolerability of a single dose of MT10109(clostridium botulinum type A) administered by intramuscular injection in subjects with glabellar lines compared with the standard dose of BOTOX®

Timeline

Start
2011-12-07
Primary completion
2012-03-30
Completion
2012-08-17

Drugs

EvaluationDrugModalityDoseRoute
Subject NivobotulinumtoxinA Protein / enzyme biologic Intramuscular

Indications

No indication recorded.